Streetbeat News

Revenues

HAIN

Hain Celestial has announced its target of achieving $130M - $150M in annualized savings and a $165M conversion of working capital cash by FY27.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 11:44 am

SLQT

SelectQuote has provided its fiscal year 2024 guidance, expecting revenues to range between $1.05 billion and $1.2 billion, which is in line with the estimated $1.1 billion. The company also anticipates a net loss between $50 million and $22 million, and an adjusted EBITDA between $80 million and $105 million.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 11:34 am

MRNA

Moderna plans to add $10B-$15B in annual sales by 2028 from new products in oncology, rare, and latent diseases. This is in addition to the previously announced $8B-$15B of expected sales from the respiratory franchise in 2027. The company will invest approximately $25 billion in research and development from 2024 through 2028 to support this growth.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 10:38 am

IMRN

Immuron reported a 7984% increase in monthly sales of its over-the-counter gastrointestinal and digestive health immune supplement, Travelan, in August 2023, reaching A$1.18M compared to A$14,581 a year ago. This follows the resolution of short term stock outages of Travelan in some wholesalers and pharmacies in the June 2023 quarter.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 10:19 am

CODA

Coda Octopus Group has revised its FY23 revenue expectations to be in line with FY22's $22.2M, down from the previous target of $26M. This is due to the slow pace of conversion of opportunities into firm orders during Q3 2023.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 10:05 am

AAPL

The Chinese government has expressed concerns over 'security incidents' involving Apple Inc.'s iPhones, according to a statement by Chinese Foreign Ministry spokeswoman Mao Ning. This comes amid reports of China banning iPhones and other foreign-made devices. However, Ning denied any official ban on iPhones. China accounts for 19% of Apple's revenue, making it a key market for the company.

Portfolio Pulse from Rounak Jain

September 13, 2023 | 9:02 am

EWU

The U.K. trade balance for July was reported at -14.06B, better than the estimated -16.00B and the prior figure of -15.46B. The trade balance with non-EU countries for July was -2.36B, an improvement from the prior -2.77B.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 6:05 am

EWU

The U.K.'s monthly Gross Domestic Product (GDP) 3M/3M change for July was reported at 0.2%, which is slightly below the estimated 0.3% and equal to the prior figure of 0.2%.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 6:04 am

INNV

InnovAge (INNV) has projected its total revenues for FY24 to be between $725M and $775M, with an estimate of $742.41M.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 8:54 pm

ATAI

CMPS

CYBN

JAZZ

JNJ

MNMD

NUMIF

PFE

PHRRF

SILO

NY-based consulting firm Research Nester predicts the global market for psychedelic substances will grow at a CAGR of around 14% over the next 12 years, reaching $12 billion by 2035. The report features key players such as COMPASS Pathways, Silo Pharma, Numinus Wellness, Cybin, Mind Medicine, PharmaTher Holdings, atai Life Sciences, Jazz Pharmaceuticals, Janssen Pharmaceuticals, and Pfizer. The growth is attributed to increased demand for psychedelic drugs to treat mental health issues, reduced production costs due to the pandemic, and increased investment in R&D.

Portfolio Pulse from Lara Goldstein

September 12, 2023 | 8:35 pm